Autopsy report · NCT00041470

Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial

“Sponsor withdrew the study”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 4 months after it had already started.
• Ran for about 7 years 5 months before it stopped.
• 38 participants enrolled.
• Results were posted on the registry 8 years 10 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

University of Washington

Sponsor type

University, hospital or other

Conditions

Breast Cancer

Interventions

Paclitaxel; Vinorelbine; Herceptin; Filgrastim

Participants

38

Sites

1

Countries

United States

Trials that died the same way

• Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab
  “Study withdrawn by Sponsor” (94% match in meaning)
• NRX-1074 in Early Course Schizophrenia
  “The study was withdrawn by the sponsor.” (94% match in meaning)
• A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy
  “Study was withdrawn per sponsor decision” (93% match in meaning)
• Safety and Efficacy of Lenvatinib in Subjects With HCC Progression After First Line Treatment With Checkpoint Inhibitors
  “The sponsor withdrawed the sponsorship to the study.” (92% match in meaning)
• Serum-Free Thymus Transplantation in DiGeorge Anomaly
  “The sponsor decided to withdraw the study.” (92% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.